Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

Starting soon · Phase 2 · Has a placebo group

Conditions studied: MSA - Multiple System Atrophy, MSA

In brief

This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.

Key facts

Study ID

NCT07465198

Run by

Biocells Medical

People needed

50

Starts

2026-09-01

Expected to finish

2031-03-01

Last updated by the study team

2026-03-11

Who can join

Age: 35 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Multiple System Atrophy (MSA-P or MSA-C)
• Age range of 35 to 65 years

You may not qualify if…

• Other major neurological disorders
• Severe cardiac/renal/hepatic impairment
• Prior stem cell therapy

Where it is running

• BioCells Medical — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.